ACOR Financial Facts
Total net revenues: 135.61MInterest and amortization of debt discount expense: -4.4M
See Full Income Statement
Non-current portion of deferred license revenue: 34.72M
Accumulated deficit: -240.88M
See Full Balance Sheet
Acorda Therapeutics, Inc. (ACOR) Earnings
|
Expand Research on ACOR
Next EPS Date | N/A | EPS Growth Rate | -139.7% *Last Qtr. |
---|---|---|---|
Average EPS % Beat Rate | -188.2% | Revenue Growth Rate | +63.1% *Last Qtr. |
Average % Move 1-Wk after EPS | -8.4% | Normal Earnings Time | After Close |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
10/22/15 | Q315 | $0.31 | $0.15 | +$0.16 | $148.2M | $115.52M | N/A | Details | |||
10/31/18 | Q318 | $0.17 | -$0.02 | +$0.19 | $142.81M | $82.81M | = | Details | |||
5/2/19 | Q119 | -$0.56 | -$0.94 | +$0.38 | $44.14M | $33.04M | = | Details | |||
2/13/14 | Q413 | $0.32 | $0.18 | +$0.14 | $92.59M | $89.96M | N/A | Details | |||
10/31/12 | Q312 | $0.38 | $0.10 | +$0.28 | $77.44M | $75.2M | N/A | Details | |||
11/4/11 | Q311 | $0.40 | $0.73 | -$0.33 | $93.03M | $90.78M | N/A | Details | |||
11/4/19 | Q319 | -$0.46 | -$0.51 | +$0.05 | $47.7M | $44.72M | = | Details | |||
8/2/18 | Q218 | $1.40 | $0.72 | +$0.68 | $153.3M | $138.63M | = | Details |